High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury

References

• Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. 2019;132(7):802–807. doi:10.1016/j.amjmed.2019.03.001
   PubMed Web of Science ®Google Scholar
• Jankovic J, Tan EK. Parkinson’s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–808. doi:10.1136/jnnp-2019-322338
   PubMed Web of Science ®Google Scholar
• Xie X, Luo X, Xie M, Liu Y, Wu T. Risk of lung cancer in parkinson’s disease. Oncotarget. 2016;7(47):77319–77325. doi:10.18632/oncotarget.12964
   PubMedGoogle Scholar
• Xie X, Luo X, Xie M. Association between parkinson’s disease and risk of colorectal cancer. Parkinsonism Relat Disord. 2017;35:42–47. doi:10.1016/j.parkreldis.2016.11.011
   PubMed Web of Science ®Google Scholar
• Tacik P, Curry S, Fujioka S, et al. Cancer in parkinson’s disease. Parkinsonism Relat Disord. 2016;31:28–33. doi:10.1016/j.parkreldis.2016.06.014
   PubMed Web of Science ®Google Scholar
• Espay AJ, Kalia LV, Gan-Or Z, et al. Disease modification and biomarker development in parkinson disease: revision or reconstruction? Neurology. 2020;94(11):481–494. doi:10.1212/WNL.0000000000009107
   PubMed Web of Science ®Google Scholar
• Mehdi SJ, Ali A, Rizvi MM. Parkin gene alterations in ovarian carcinoma from northern Indian population. Pathol Oncol Res. 2011;17(3):579–586. doi:10.1007/s12253-010-9351-x
   PubMed Web of Science ®Google Scholar
• Picchio MC, Martin ES, Cesari R, et al. Alterations of the tumor suppressor gene parkin in non-small cell lung cancer. Clin Cancer Res. 2004;10(8):2720–2724. doi:10.1158/1078-0432.CCR-03-0086
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Marusawa H, Wang HQ, et al. Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene. 2008;27(46):6002–6011. doi:10.1038/onc.2008.199
   PubMed Web of Science ®Google Scholar
• Morris LG, Veeriah S, Chan TA. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene. 2010;29(24):3453–3464. doi:10.1038/onc.2010.127
   PubMed Web of Science ®Google Scholar
• Wahabi K, Perwez A, Rizvi MA. Parkin in parkinson’s disease and cancer: a double-edged sword. Mol Neurobiol. 2018;55(8):6788–6800. doi:10.1007/s12035-018-0879-1
   PubMed Web of Science ®Google Scholar
• Ejma M, Madetko N, Brzecka A, et al. The links between parkinson’s disease and cancer. Biomedicines. 2020;8(10):10. doi:10.3390/biomedicines8100416
   PubMed Web of Science ®Google Scholar
• Wang XM, Zhang YG, Li AL, et al. Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with parkinson’s disease. Eur Rev Med Pharmacol Sci. 2016;20(18):3853–3856.
   PubMed Web of Science ®Google Scholar
• Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in parkinson’s disease. Neuroscience. 2015;302:89–102. doi:10.1016/j.neuroscience.2014.10.028
   PubMed Web of Science ®Google Scholar
• Nalls MA, Saad M, Noyce AJ, et al. Genetic comorbidities in parkinson’s disease. Hum Mol Genet. 2014;23(3):831–841. doi:10.1093/hmg/ddt465
   PubMed Web of Science ®Google Scholar
• Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100(1):34–41. doi:10.1111/j.1600-0404.1999.tb00721.x
   PubMed Web of Science ®Google Scholar
• Saunders JA, Estes KA, Kosloski LM, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in PARKINSON’S disease. J Neuroimmune Pharmacol. 2012;7(4):927–938. doi:10.1007/s11481-012-9402-z
   PubMed Web of Science ®Google Scholar
• Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of parkinson disease. J Clin Invest. 2009;119(1):182–192. doi:10.1172/JCI36470
   PubMed Web of Science ®Google Scholar
• Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3(1):e1376. doi:10.1371/journal.pone.0001376
   PubMed Web of Science ®Google Scholar
• Galaine J, Borg C, Godet Y, Adotevi O. Interest of tumor-specific CD4 T helper 1 cells for therapeutic anticancer vaccine. Vaccines. 2015;3(3):490–502. doi:10.3390/vaccines3030490
   Google Scholar
• Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–933. doi:10.1001/jamaneurol.2016.1399
   PubMed Web of Science ®Google Scholar
• Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16(4):589–593. doi:10.1093/neuonc/nou001
   PubMed Web of Science ®Google Scholar
• Keystone E, Alkhalaf A, Makkawy M. Subcutaneous abatacept in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2015;15(8):1221–1230. doi:10.1517/14712598.2015.1065248
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care. 2014;37(4):1069–1075. doi:10.2337/dc13-0604
   PubMed Web of Science ®Google Scholar
• Del Bello A, Marion O, Milongo D, Rostaing L, Kamar N. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. Expert Rev Clin Pharmacol. 2016;9(2):215–227. doi:10.1586/17512433.2016.1112736
   PubMed Web of Science ®Google Scholar
• Baksh K, Weber J. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42(3):363–377. doi:10.1053/j.seminoncol.2015.02.015
   PubMed Web of Science ®Google Scholar
• Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017;16(10):1049–1057. doi:10.1016/j.autrev.2017.07.022
   PubMed Web of Science ®Google Scholar
• Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2020;64:1–12. doi:10.1016/j.semcancer.2019.06.001
   PubMed Web of Science ®Google Scholar
• Tan EK, Chao YX, West A, Chan LL, Poewe W, Jankovic J. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020;16(6):303–318. doi:10.1038/s41582-020-0344-4
   PubMed Web of Science ®Google Scholar